期刊
LEUKEMIA & LYMPHOMA
卷 57, 期 4, 页码 909-920出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1086918
关键词
Cytarabine; acute myeloid leukemia; event-free survival; gene expression
资金
- NCATS NIH HHS [UL1 TR001427] Funding Source: Medline
- NCI NIH HHS [P30CA021765, R01CA132946, P30 CA021765, R01 CA132946] Funding Source: Medline
Despite initial remission, similar to 60-70% of adult and 30% of pediatric patients experience relapse or refractory AML. Studies so far have identified base line gene expression profiles of pathogenic and prognostic significance in AML; however, the extent of change in gene expression post-initiation of treatment has not been investigated. Exposure of leukemic cells to chemotherapeutic agents such as cytarabine, a mainstay of AML chemotherapy, can trigger adaptive response by influencing leukemic cell transcriptome and, hence, development of resistance or refractory disease. It is, however, challenging to perform such a study due to lack of availability of specimens post-drug treatment. The primary objective of this study was to identify in vivo cytarabine-induced changes in leukemia cell transcriptome and to evaluate their impact on clinical outcome. The results highlight genes relevant to cytarabine resistance and support the concept of targeting cytarabine-induced genes as a means of improving response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据